>
Bio-UV SA logo

ALTUV - Bio-UV SA Share Price

€5.72 -0.1  -0.9%

Last Trade - 4:38pm

Sector
Industrials
Size
Small Cap
Market Cap £50.2m
Enterprise Value £51.1m
Revenue £27.4m
Position in Universe 599th / 841
Bullish
Bearish
Unlock ALTUV Revenue
Momentum
Relative Strength (%)
1m -0.64%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 11.2 10.2 12.4 20.0 32.2 40.6 48.5 +30.2%
+71.1 +29.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, Bio-UVGroup SA revenues increased 61% to EUR32.2M. Net incometotaled EUR584K vs. loss of EUR448K. Revenues reflectHistorical Activities segment increase of 76% to EUR17.1M,Ballast Activities segment increase of 47% to EUR15M,Europe (excl. France) segment increase of 71% to EUR10.5M,France segment increase of 73% to EUR10.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALTUV Revenue Unlock ALTUV Revenue

Net Income

ALTUV Net Income Unlock ALTUV Revenue

Normalised EPS

ALTUV Normalised EPS Unlock ALTUV Revenue

PE Ratio Range

ALTUV PE Ratio Range Unlock ALTUV Revenue

Dividend Yield Range

ALTUV Dividend Yield Range Unlock ALTUV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALTUV EPS Forecasts Unlock ALTUV Revenue
Profile Summary

Bio-Uv Group SAS is a France-based company, which operates as a manufacturer of ultraviolet light water treatment equipment. The Company designs, manufactures and markets systems and concepts of disinfection by ultraviolet light (UV-C) adapted to a number of applications, which enable automatic chlorine-free treatment for residential and collective swimming pools and spas. Bio-Uv Group SAS divides its range of products into two main segments: Individual, which includes residential pools & spas, fish ponds and aquariums and domestic drinking water for human consumption, and Professionals, which includes commercial pools and spas for professionals, water treatment, ballast water treatment, aquaculture, aquariums and fountains, among others.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 13, 2010
Public Since July 10, 2018
No. of Shareholders: n/a
No. of Employees: 114
Sector Industrials
Industry Machinery, Equipment & Components
Index
Exchange Euronext - Paris
Shares in Issue 10,215,554
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALTUV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALTUV
Upcoming Events for ALTUV
Frequently Asked Questions for Bio-UV SA
What is the Bio-UV SA share price?

As of 4:38pm, shares in Bio-UV SA are trading at €5.72, giving the company a market capitalisation of £50.2m. This share price information is delayed by 15 minutes.

How has the Bio-UV SA share price performed this year?

Shares in Bio-UV SA are currently trading at €5.72 and the price has moved by -5.41% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bio-UV SA price has moved by -25.59% over the past year.

What are the analyst and broker recommendations for Bio-UV SA?

Of the analysts with advisory recommendations for Bio-UV SA, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bio-UV SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bio-UV SA next release its financial results?

Bio-UV SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bio-UV SA dividend yield?

Bio-UV SA does not currently pay a dividend.

Does Bio-UV SA pay a dividend?

Bio-UV SA does not currently pay a dividend.

When does Bio-UV SA next pay dividends?

Bio-UV SA does not currently pay a dividend.

How do I buy Bio-UV SA shares?

To buy shares in Bio-UV SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bio-UV SA?

Shares in Bio-UV SA are currently trading at €5.72, giving the company a market capitalisation of £50.2m.

Where are Bio-UV SA shares listed? Where are Bio-UV SA shares listed?

Here are the trading details for Bio-UV SA:

Country of listing: France
Exchange: PAR
Ticker Symbol: ALTUV
What kind of share is Bio-UV SA?

Based on an overall assessment of its quality, value and momentum, Bio-UV SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bio-UV SA share price forecast 2021?

Shares in Bio-UV SA are currently priced at €5.72. At that level they are trading at 25.65% discount to the analyst consensus target price of 0.00.

Analysts covering Bio-UV SA currently have a consensus Earnings Per Share (EPS) forecast of 0.17 for the next financial year.

How can I tell whether the Bio-UV SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio-UV SA. Over the past six months, the relative strength of its shares against the market has been -23.23%. At the current price of €5.72, shares in Bio-UV SA are trading at -3.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bio-UV SA PE Ratio?

The Bio-UV SA PE ratio based on its reported earnings over the past 12 months is 58.09. The shares are currently trading at €5.72.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bio-UV SA?

Bio-UV SA's management team is headed by:

Benoit Gillmann - CHM
Laurent Emmanuel Migeon - DCE
Xavier Bayle - DRC
Thierry Noel - DRC
Genevieve Blanc - DRC
Anne Lardoux de Pazzis - IND
Who are the major shareholders of Bio-UV SA?

Here are the top five shareholders of Bio-UV SA based on the size of their shareholding:

Gillmann (Benoit) Individual Investor
Percentage owned: 21.54% (2.23m shares)
Atalaya Capital Management LP Investment Advisor/Hedge Fund
Percentage owned: 6.73% (697k shares)
DNCA Investments Investment Advisor
Percentage owned: 5.3% (548k shares)
DNCA Actions Euro Micro Caps Mutual Fund
Percentage owned: 4.23% (437k shares)
Ostrum Asset Management Investment Advisor
Percentage owned: 3.87% (400k shares)
Similar to ALTUV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.